文献速递前列腺癌

PSA筛查人群中前列腺穿刺阴性后的前列腺癌发病率与死亡率

Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.
PubMed 文献 · Urology · 2021-06-26

基于PLCO筛查试验中2855例首次穿刺阴性男性,中位随访13.2年(发病)和16.6年(死亡),20年前列腺癌累积发病率为26.4%(95%CI: 24.8-28.1),死亡率为1.2%(95%CI: 0.9-1.7);PSA升高与发病和死亡风险显著增加相关。

要点

  • 穿刺阴性后20年前列腺癌累积死亡率为1.2%,总体风险低。
  • 20年累积发病率为26.4%,需持续监测。
  • PSA水平升高与前列腺癌发病和死亡风险显著增加相关。

核心结论

  • 穿刺阴性后20年内前列腺癌死亡率低,但发病率仍达26.4%。
  • PSA水平升高与前列腺癌发病和死亡风险显著增加相关。

研究设计与样本

  • 基于PLCO癌症筛查随机试验,纳入干预组中PSA>4 ng/mL或DRE阳性后1年内穿刺阴性的2855例男性。
  • 中位年龄65岁,穿刺发生于1994-2006年,发病中位随访13.2年,死亡中位随访16.6年。

主要发现

  • 共诊断740例前列腺癌,33例前列腺癌死亡。
  • 20年累积前列腺癌发病率为26.4%(95%CI: 24.8-28.1),死亡率为1.2%(95%CI: 0.9-1.7)。
  • PSA水平升高与前列腺癌发病和死亡风险显著增加相关(多因素Cox回归)。

临床怎么用

  • 穿刺阴性后应继续PSA监测,尤其PSA较高者。
  • 需告知患者穿刺阴性后仍有长期发病风险,但死亡风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transrectal ultrasound guided biopsy for diagnostic workup for prostate cancer (PCa) has a substantial false negative rate. We sought to estimate PCa incidence and mortality following negative biopsy in a cohort of men undergoing prostate cancer screening. SUBJECTS AND METHODS: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial randomized participants 55-74 years to an intervention vs control arm. Intervention arm men received annual prostate-specific antigen (PSA) tests for 6 years and digital rectal exams (DRE) for 4 years. We examined the cohort of men with a positive PSA (> 4 ng/mL) or DRE screen followed within one year by a negative biopsy. PCa incidence and mortality rates from time of first negative biopsy were analyzed as a function of PSA level at diagnosis and other factors. Cumulative incidence and mortality rates accounting for competing risk were estimated. Multivariate proportional hazards regression was utilized to estimate hazard ratios (HRs) of PCa outcomes by PSA level, controlling for age and race. RESULTS: The negative biopsy cohort included 2855 men. Median (25th/75th) age at biopsy was 65 (61/69) years; biopsies occurred between 1994 and 2006. Median (25/75th) follow-up was 13.2 (6.5/16.8) years for incidence and 16.6 (12.3/19.2) years for mortality. 740 PCa cases were diagnosed, with 33 PCa deaths. Overall 20-year cumulative PCa incidence and mortality rates were 26.4% (95% CI: 24.8-28.1) and 1.2% (95% CI: 0.9-1.7), respectively. HRs for PCa incidence and mortality increased significantly with increasing PSA. CONCLUSION: The mortality rate from PCa through 20 years following a negative biopsy is low.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Pierre-Victor D, Parnes HL, Andriole GL, et al. Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening. Urology. 2021. PMID: 34186135. doi:10.1016/j.urology.2021.05.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。